This is a preview of subscription content, log in via an institution to check access.
Notes
The study was partly funded by Pfizer.
Costs were reported in Chinese renminbi and US dollars, and long- term costs were discounted at 5% per annum.
Reference
Liu G, et al. Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China. Clinical Therapeutics : 12 Aug 2021. Available from: URL: http://doi.org/10.1016/j.clinthera.2021.07.004
Rights and permissions
About this article
Cite this article
Prophylactic factor IX therapy cost effective for children with haemophilia B in China. PharmacoEcon Outcomes News 886, 17 (2021). https://doi.org/10.1007/s40274-021-07995-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-07995-6